Case-control study of colorectal cancer and fecal mutagenicity.
Fecal mutagenicity was measured in 68 patients with colorectal cancer and in 114 controls, using Salmonella tester strains TA98 and TA100 with and without S9 activation. Samples were also tested for fecapentaenes by high-performance liquid chromatography, to permit the separation of fecapentaene and non-fecapentaene mutagenicity. Overall, no significant case-control differences in fecal mutagenicity were observed. However, when samples containing high concentrations of fecapentaenes were excluded, non-fecapentaene TA98 mutagenicity was observed in eight cases (12%) and only four controls (4%), resulting in an estimated relative risk of 4.4 (95% confidence interval = 1.0-21.1). The association of colorectal cancer risk with non-fecapentaene TA98 mutagenicity could not be explained as an artifact of diagnostic workup or gastrointestinal bleeding among the cases. Smoking could also be excluded as a source of the TA98 mutagenicity seen, but possible dietary origins are still being explored.
Schiffman
M H
MH
Epidemiology and Biostatistics Program, Division of Cancer Etiology, National Cancer Institute, Bethesda, Maryland 20892.
Andrews
A W
AW
Van Tassell
R L
RL
Smith
L
L
Daniel
J
J
Robinson
A
A
Hoover
R N
RN
Rosenthal
J
J
Weil
R
R
Nair
P P
PP
D000230:Adenocarcinoma / Q000503:physiopathology*; D003110:Colonic Neoplasms / Q000503:physiopathology*; D005243:Feces / Q000032:analysis*; D006801:Humans; D009152:Mutagenicity Tests; D009153:Mutagens / Q000032:analysis* / Q000302:isolation & purification / Q000494:pharmacology; D012004:Rectal Neoplasms / Q000503:physiopathology*; D012016:Reference Values; D012486:Salmonella typhimurium / Q000187:drug effects
D009153:Mutagens